

A Unique Formulation Reduces Hunger & Craving¹⁻³



- ✓ Significant weight loss began early at week 4 & sustained to week 56⁴
- ✓ Help change eating behaviour from week 8 of treatment^{2,4}

- ✓ 3 times more likely to lose at least 5% to 10% of bodyweight⁴
- ✓ EMA and US FDA Approved^{5*}

Reference: 1. Contrave Product Information. 2. Billes SK et al. Pharmacol Res 2014;84:1-11. 3. Drug Office, Department of Health, Government of HKSAR. Search Drug Database search of 'bupropion' and 'naltrexone'. Apr 2021. Available at: https://www.drugoffice.gov.hk/eps/do/en/consumer/search_drug_database.html. 4. Greenway FL et al. Lancet 2010;376:595-605. 5. Yumuk V et al. Obes Facts 2015;8:402-424.

*European Medicines Agency (EMA; Mysimba®); US Food and Drug Administration (US FDA; Contrave®). Approved for weight management as an adjunct to diet and exercise in adult patients with a BMI of $\geq 30\text{kg/m}^2$ or overweight $\geq 27\text{kg/m}^2$ with weight related comorbidities.



Please refer to full PI before prescribing.
Further information is available on request from Inova Pharmaceuticals.

Email: enquiries.hkg@inovapharma.com
<http://www.inovapharma.com>

For Healthcare Professionals Only

HK-2021-10-006